201 related articles for article (PubMed ID: 38588933)
1. Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
Dehghanian F; Ghahnavieh LE; Nilchi AN; Khalilian S; Joonbakhsh R
Gene; 2024 Jul; 916():148424. PubMed ID: 38588933
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.
Mohajan S; Jaiswal PK; Vatanmakarian M; Yousefi H; Sankaralingam S; Alahari SK; Koul S; Koul HK
Cancer Lett; 2021 Jun; 507():112-123. PubMed ID: 33737002
[TBL] [Abstract][Full Text] [Related]
4. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?
Margariti N; Fox SB; Bottini A; Generali D
Breast Cancer Res Treat; 2011 Aug; 128(3):599-606. PubMed ID: 20945086
[TBL] [Abstract][Full Text] [Related]
5. Hippo pathway in mammary gland development and breast cancer.
Shi P; Feng J; Chen C
Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):53-9. PubMed ID: 25467757
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
7. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.
Peng L; Jiang J; Tang B; Nice EC; Zhang YY; Xie N
Theranostics; 2020; 10(23):10360-10377. PubMed ID: 32929354
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
He Z; Zhao TT; Jin F; Li JG; Xu YY; Dong HT; Liu Q; Xing P; Zhu GL; Xu H; Miao ZF
Biochem Biophys Res Commun; 2018 Sep; 503(4):2340-2347. PubMed ID: 29964010
[TBL] [Abstract][Full Text] [Related]
9. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
10. Emerging roles of exosomal miRNAs in breast cancer drug resistance.
Najminejad H; Kalantar SM; Abdollahpour-Alitappeh M; Karimi MH; Seifalian AM; Gholipourmalekabadi M; Sheikhha MH
IUBMB Life; 2019 Nov; 71(11):1672-1684. PubMed ID: 31322822
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
12. Hippo signaling pathway: A comprehensive gene expression profile analysis in breast cancer.
Yousefi H; Delavar MR; Piroozian F; Baghi M; Nguyen K; Cheng T; Vittori C; Worthylake D; Alahari SK
Biomed Pharmacother; 2022 Jul; 151():113144. PubMed ID: 35623167
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis.
Chen W; Zhou S; Mao L; Zhang H; Sun D; Zhang J; Li J; Tang JH
Tumour Biol; 2016 Aug; 37(8):10011-9. PubMed ID: 27153853
[TBL] [Abstract][Full Text] [Related]
14. The Hippo pathway as a drug target in gastric cancer.
Qiao Y; Li T; Zheng S; Wang H
Cancer Lett; 2018 Apr; 420():14-25. PubMed ID: 29408652
[TBL] [Abstract][Full Text] [Related]
15. The Hippo pathway in chemotherapeutic drug resistance.
Zhao Y; Yang X
Int J Cancer; 2015 Dec; 137(12):2767-73. PubMed ID: 25348697
[TBL] [Abstract][Full Text] [Related]
16. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
17. Drug target strategies in breast cancer treatment: recent developments.
Mayank ; Jaitak V
Anticancer Agents Med Chem; 2014; 14(10):1414-27. PubMed ID: 24712325
[TBL] [Abstract][Full Text] [Related]
18. INHBA regulates Hippo signaling to confer 5-FU chemoresistance mediated by cellular senescence in colon cancer cells.
Zhang Z; Chen L; Yang Q; Tang X; Li J; Zhang G; Wang Y; Huang H
Int J Biochem Cell Biol; 2024 Jun; 171():106570. PubMed ID: 38588888
[TBL] [Abstract][Full Text] [Related]
19. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.
Zhang Y
Pharmacol Ther; 2021 Feb; 218():107677. PubMed ID: 32898548
[TBL] [Abstract][Full Text] [Related]
20. Mitigation of Breast Cancer Cells' Invasiveness via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles.
Roy M; Hussain F
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
